The SeptiCyte™ technology rapidly quantifies specific biomarkers to aid clinicians in the early identification
of infection in suspected sepsis patients.
By testing whole blood directly, the assay is able to detect the response of the patient’s immune system to an infection earlier, faster and more accurately than finding the pathogen.
Understanding Host Response to create better diagnostic tools
Determining infection status in suspected sepsis patients has traditionally focused
on finding and characterizing the invading pathogen.
Finding and characterizing the invading pathogen is often slow with no identification in the majority of suspected sepsis cases.
However, the immune system responds specifically to an invading pathogen and produces an abundant genetic signal
that is reliably detected by SeptiCyte™ technology.
Specific Host Response
How to improve accuracy and accessibility to rapid clinical test results?
Do not focus only on identifying the pathogen.
The immune system holds the key to unlocking better understanding, diagnosis and treatment
of patients suspected of sepsis by using the specific host response.
Immune cells contain large amounts of RNA – a measurable genetic material that is a snapshot of the immune conversation.
Using mathematical algorithms, patient’s genetic material from the septic immune response is rapidly analyzed providing actionable clinical information in 100% of suspected sepsis cases.
Immunexpress’ SeptiCyte™ LAB is the only FDA cleared test for the management of sepsis using the patient's genomic response to infection. Multi-national clinical trials have shown SeptiCyte™ to be the single most accurate test for the diagnosis of sepsis.
Accuracy and Accessibility
Minimize the chance of false negative and false positive results by combining data
from a host response assay WITH pathogen information.
SeptiCyte™ host response results allow clinicians to better interpret positive and negative pathogen results.
Benefits of Early, Accurate Diagnosis
Immunexpress has granted patents and applications in key markets that cover sepsis diagnostic technology
measuring the host immune response.
Claims include biomarkers, algorithms, analysis methods, treatments, compositions and kits.
These patents include combinations of biomarkers for differentiating sepsis and SIRS, diagnosing bacterial, viral,
herpes and protozoal infections, and differentiating pathogenic bacteria.
About SeptiCyte™ LAB
Immunexpress’ pipeline includes several assays for readily available instruments,
including random access, point-of-care (POC) and sample-to-answer.
SeptiCyte™ LAB received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its use as an aid in differentiating infection-positive (sepsis) from infection-negative (SIRS) systemic inflammation
in critically ill patients on their first day of ICU admission.
Find out more here.
About SeptiCyte™ RAPID
In Jan. 2018, Immunexpress entered into an agreement with Biocartis to develop and commercialize Immunexpress’ SeptiCyte™ test for use on Biocartis’ sample-to-result Idylla™ platform. The collaboration promises a fully-automated, rapid near-patient host response test that quickly provides accurate life-saving clinical information.
In sepsis diagnosis, every minute counts!
Clinicians are working against the clock when treating sepsis. Our goal is to transform sepsis diagnostics by providing clinicians with the technology to rapidly enable and confidently make the right treatment decisions.
In January 2018, we announced a partnership with Biocartis to develop and commercialize a fully automated SeptiCyte™ LAB test for use on the Biocartis’ sample-to-answer real-time PCR Idylla™ platform.
Revolutionize sepsis detection. Fast. Easy. Reliable.
This is a unique, real time PCR (Polymerase Chain Reaction) system offering highly-reliable
molecular information in virtually any lab setting.
2 minutes handling time. Less than 90 minutes for results.
The combination of Immunexpress’ SeptiCyte™ technology with Biocartis’ Idylla™ platform empowers physicians to swiftly differentiate sepsis from SIRS in critically ill patients.
SeptiCyte™ technology uses proprietary biomarker signatures to assess the response of a patient’s immune system to infections to provide clinically meaningful data for optimized treatment. By leveraging the rapid turn-around time of the Idylla™ platform, outcomes are improved and costs reduced.
For each hour delay in diagnosis, the chance of death increases by 8%.1 In one large multi-site study measuring the economic impact of delays in sepsis diagnosis, the average cost per patient linked to a delay in diagnosis was in excess of $20K.2
Under the partnership, Immunexpress and Biocartis will codevelop the SeptiCyte™ LAB test onto the Idylla platform, allowing results to be generated in a timeframe that supports the time-critical decision-making
required in the management of sepsis patients.
 Kumar, Anand, et al. "Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock." Critical care medicine 34.6 (2006): 1589-1596.
 Paoli, Carly J., et al. "Epidemiology and Costs of Sepsis in the United States-An Analysis Based on Timing of Diagnosis and Severity Level." Critical care medicine (2018).